Uncategorized

Uncategorized

New Releases from NCBI BookshelfAnti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis [Internet].​Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis [Internet].

Diabetic retinopathy is a major cause of sight loss in people with diabetes. The most severe form, proliferative diabetic retinopathy,

Uncategorized

New Releases from NCBI BookshelfElafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].​Elafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Iqirvo be reimbursed by public drug plans for the treatment of primary biliary cholangitis

Uncategorized

New Releases from NCBI BookshelfPolatuzumab Vedotin (Polivy): Indication: Polivy (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL that are classified as activated B-cell-like (ABC) lymphoma subtype: Reimbursement Recommendation [Internet].​Polatuzumab Vedotin (Polivy): Indication: Polivy (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL that are classified as activated B-cell-like (ABC) lymphoma subtype: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Polivy in combination with rituximab, cyclophosphamide, doxorubicin , and prednisone (R-CHP) should be reimbursed

Uncategorized

New Releases from NCBI BookshelfMolecular imaging is non-inferior to adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient study.​Molecular imaging is non-inferior to adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient study.

Primary aldosteronism due to a unilateral aldosterone-producing adenoma is a common cause of hypertension. This can be cured or greatly

Scroll to Top